Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

This early access program is for a very serious condition called acute Graft-versus-Host Disease (aGvHD) that affects the gut. aGvHD can happen to people who have had a special type of transplant called a stem cell transplant, where new, healthy cells are given to them. Sometimes, these new cells see the patient's body as 'foreign' and start to attack it. When this attack happens in the gut, it can cause severe problems like bad diarrhoea and stomach pain.

The most common treatment for aGvHD is with medicines called steroids. However, for some people, these steroids don't work, or they stop working. This is called 'steroid-refractory' aGvHD. For these patients, there are very few other treatment options, and the condition can be life-threatening. This program offers a new, experimental treatment called MaaT013, which is still being tested and hasn't been officially approved for sale yet.

MaaT013 is a special type of medicine that uses healthy gut bacteria, called 'pooled allogeneic fecal microbiota.' It's hoped that by introducing these healthy bacteria, it can help calm down the gut and reduce the severe symptoms of aGvHD when other treatments have failed. This early access program is a way to provide this experimental treatment to patients who desperately need it, while larger studies are still underway to fully understand how well it works and if it's safe for everyone. It's an important step for patients with very limited choices.